Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageBaxter International Inc., through our subsidiaries, provides a broad portfolio of essential healthcare products, including sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices.
In the company’s own words · 10-K filed Feb 12, 2026 · SEC EDGAR
Business segments
Q2 2026 · $1.54BThe company’s own SEC segment disclosure.
- Infusion Therapies And Platforms$769.0M50%
- Care And Connectivity Solutions$361.0M23%
- Front Line Care$226.0M15%
- Advanced Surgery$182.0M12%
Baxter International (BAX) reported revenue of $2.70B in Q1 2026 (quarter ended March 31, 2026), up 2.9% from the same quarter a year earlier. That came with a gross margin of 33% and net loss of $15M. For the full year FY2025, revenue was $11.2B (+5.7% year on year) and net income −$957M. Its largest product in 2026-Q2 was Infusion Therapies And Platforms at $769M, 50% of the disclosed total, just ahead of Care And Connectivity Solutions at 23%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Medical Instruments & Supplies
Ranks #20 of 27 by Smart Score